MedPath

LMB-100

Generic Name
LMB-100
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1841500-93-3
Unique Ingredient Identifier
D6AT024T4P
Background

LMB-100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity.

Associated Conditions
-
Associated Therapies
-

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Phase 1
Withdrawn
Conditions
Malignant Pleural Mesotheliomas (Mpm)
Malignant Pleural Effusions (Mpe)
Epithelial Tumors, Malignant
Mesothelin (Msln)
Pleural Effusions, Malignant
Interventions
Procedure: Cytoreductive surgery
Drug: LMB-100
Diagnostic Test: Immunohistochemical Assay for Mesothelin
First Posted Date
2022-05-17
Last Posted Date
2024-02-02
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT05375825
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Phase 1
Completed
Conditions
Neoplasms With Mesothelin Expression
Epithelioid Mesothelioma
Cholangiocarcinoma, Extrahepatic
Adenocarcinoma, Pancreatic
Interventions
Drug: LMB-100
Drug: Tofacitinib
Device: Mesothelin Expression
First Posted Date
2019-07-26
Last Posted Date
2023-08-01
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
19
Registration Number
NCT04034238
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2
Terminated
Conditions
Adenocarcinoma of Lung
Non-Small Cell Lung Cancer
Lung Cancer
Interventions
Drug: LMB-100
Drug: pembrolizumab
Diagnostic Test: Mesothelin Expression
Diagnostic Test: TrueSight Oncology 500
First Posted Date
2019-07-22
Last Posted Date
2024-04-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
6
Registration Number
NCT04027946
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

Phase 2
Terminated
Conditions
Mesothelioma
Interventions
Drug: LMB-100
Biological: Pembrolizumab
First Posted Date
2018-08-23
Last Posted Date
2021-12-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
18
Registration Number
NCT03644550
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Phase 1
Terminated
Conditions
Mesothelioma
Interventions
Drug: LMB-100
Drug: SEL-110
First Posted Date
2018-02-19
Last Posted Date
2019-11-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
5
Registration Number
NCT03436732
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

Phase 1
Completed
Conditions
Neoplasms
Pancreatic Neoplasms
Interventions
Drug: LMB-100
Drug: Nab-Paclitaxel
Device: Mesothelin Expression
First Posted Date
2016-06-23
Last Posted Date
2022-03-15
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
40
Registration Number
NCT02810418
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Phase 1
Completed
Conditions
Mesothelioma
Interventions
First Posted Date
2016-06-14
Last Posted Date
2022-08-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
21
Registration Number
NCT02798536
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath